Black Rock Inc. Eledon Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 155,080 shares of ELDN stock, worth $632,726. This represents 0.0% of its overall portfolio holdings.

Number of Shares

155,080

Previous 26,831 477.99%

Holding current value

$632,726

Previous $55,000 643.64%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.57 - $3.12 $201,350 - $400,136	128,249 Added 477.99%	155,080 $409,000
Q1 2024 May 10, 2024	SELL	$1.54 - $2.13 $2,265 - $3,133	-1,471 Reduced 5.2%	26,831 $55,000
Q2 2023 Aug 11, 2023	SELL	$1.34 - $2.85 $32,516 - $69,158	-24,266 Reduced 46.16%	28,302 $38,000
Q1 2023 May 12, 2023	BUY	$2.0 - $3.46 $1,596 - $2,761	798 Added 1.54%	52,568 $124,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $2.75 $5,218 - $6,613	2,405 Added 4.87%	51,770 $118,000
Q3 2022 Nov 14, 2022	BUY	$2.45 - $3.88 $2,631 - $4,167	1,074 Added 2.22%	49,365 $136,000
Q2 2022 Aug 12, 2022	SELL	$2.34 - $3.96 $26,339 - $44,573	-11,256 Reduced 18.9%	48,291 $118,000
Q1 2022 May 12, 2022	SELL	$3.06 - $4.89 $11,074 - $17,696	-3,619 Reduced 5.73%	59,547 $235,000
Q4 2021 Feb 10, 2022	BUY	$4.02 - $6.07 $62,945 - $95,044	15,658 Added 32.96%	63,166 $279,000
Q3 2021 Nov 09, 2021	BUY	$5.94 - $8.46 $7,211 - $10,270	1,214 Added 2.62%	47,508 $293,000
Q2 2021 Aug 11, 2021	BUY	$7.62 - $11.75 $352,760 - $543,954	46,294 New	46,294 $366,000

Others Institutions Holding ELDN

# of Institutions

Shares Held

18.4M

Call Options Held

Put Options Held

View Full List

About Eledon Pharmaceuticals, Inc.

Ticker ELDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,756,800
Market Cap $56.1M
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...

More about ELDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account